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Accepted 12 December 2016; Published online 11 May 2017AbstractResults from pragmatic trials should reflect the comparative treatment effects encountered in patients in real-life clinical practice to
guide treatment decisions. Therefore, pragmatic trials should focus on outcomes that are relevant to patients, clinical practice, and treatment
choices. This sixth article in the series (see Box) discusses different types of outcomes and their suitability for pragmatic trials, design
choices for measuring these outcomes, and their implications and challenges. Measuring outcomes in pragmatic trials should not interfere
with real-world clinical practice to ensure generalizability of trial results, and routinely collected outcomes should be prioritized. Typical
outcomes include mortality, morbidity, functional status, well-being, and resource use. Surrogate endpoints are typically avoided as primary
outcome. It is important to measure outcomes over a relevant time horizon and obtain valid and precise results. As pragmatic trials are often
open label, a less subjective outcome can reduce bias. Methods that decrease bias or enhance precision of the results, such as standardi-
zation and blinding of outcome assessment, should be considered when a high risk of bias or high variability is expected. The selection of
outcomes in pragmatic trials should be relevant for decision making and feasible in terms of executing the trial in the context of interest.
Therefore, this should be discussed with all stakeholders as early as feasible to ensure the relevance of study results for decision making in
clinical practice and the ability to perform the study.  2017 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction more frequent study-related follow-up visits could posi-Pragmatic trials focus on collecting clinical evidence on
the comparative effects of treatments that is relevant to
patients, caregivers, and therapeutic decision making rather
than on generating evidence of the direct pharmacological
or biological effect of the intervention [1e3]. The aim of
a pragmatic trial is to ensure generalizability of study
results to the target patient group that will be treated in
day-to-day clinical practice. The measurement of outcomes
should therefore not interfere with routine practice to main-
tain the real-world character of the trial [4]. For instance,* Corresponding author. Tel.: þ31-611104143.
E-mail address: p.m.j.welsing@umcutrecht.nl (P.M. Welsing).
http://dx.doi.org/10.1016/j.jclinepi.2016.12.022
0895-4356/ 2017 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).tively influence treatment adherence above that in usual
care. Apart from this direct interference, just the awareness
of being in a trial can already have an effect on behavior (an
example of the Hawthorne effect) [5]; however, following
routine clinical practice closely will probably minimize this
effect.
It can be challenging to align the real-world aspects of
the trial with a methodologically sound trial design, while
satisfying all stakeholders regarding their outcome require-
ments. Defining and operationalizing the appropriate out-
comes may therefore be a demanding task. This sixth
article in the series (see Box) discusses the challenges
and aims to provide guidance for selecting the mostess article under the CC BY-NC-ND license (http://creativecommons.org/
Box Series on pragmatic trials
Pragmatic trials aim to generate real-world evi-
dence on the (relative) effects of treatments, general-
izable to routine practice. In this series, we will
discuss options and choices for pragmatic trial design,
operational consequences, and the interpretation of
results.
1. Introduction
2. Setting, sites, and investigator selection
3. Patient selection challenges and consequences
4. Informed consent
5. Usual care and real life comparators
6. Outcome measures in the real world
7. Safety, quality and monitoring
8. Data collection and management
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Key findings
 Outcomes in pragmatic trials should be relevant for
patients, physicians, and clinical decision making.
Surrogate endpoints should generally be avoided.
 Typical outcomes include mortality, morbidity,
functional status, well-being, and resource use
measured over a relevant time horizon irrespective
of whether the treatment protocol is followed.
 As pragmatic trials are often open label, the inclu-
sion of objective outcome measures can reduce the
risk of bias. Routinely collected outcomes should
be prioritized.
What this adds to what was known?
 This article discusses the challenges and provides
guidance for selecting the most appropriate out-
comes in pragmatic trials and measuring them with
minimal impact on routine clinical practice.
What is the implication and what should change
now?
 Outcome measurements should interfere with clin-
ical practice as little as possible, but standardiza-
tion and blinding of outcome assessment should
be considered when there is a high risk of bias or
high variability is expected.
 Patients who are not treated according to the proto-
col should remain followed for the collection of
outcome data if possible to enable a true
intention-to-treat analysis.
 The selection of outcomes in pragmatic trials
should be discussed with all stakeholders to ensure
the relevance of study results for decision making
in clinical practice and the ability to perform the
study.
appropriate outcomes in pragmatic trials and measuring
them with minimal impact on routine clinical practice.
2. Selection of outcome measures
An outcome is the result of a process or an event. In
trials, an outcome (or endpoint) is a measurable change
in health or quality of life that can be influenced by treat-
ment [6]. Outcomes in clinical trials generally relate to
mortality, pathophysiological manifestations related to the
disease process, morbidity, functional status, quality of life,
and/or resource use and costs, as shown in Fig. 1 [7,8]. The
full impact of a treatment on patients’ health is of key
100 P.M. Welsing et al. / Journal of Clinterest but may become apparent only after several years
of follow-up, which may challenge the feasibility of the
study in terms of its duration and costs.
As depicted in Fig. 1, it is important to consider different
types of outcomes and discuss them with all stakeholders
including an assessment of what is measured in the usual
practice settings and the comparability of outcomes with
those used in previous similar studies [7,8]. Feasibility, inter-
ference with practice, validity, and precision of measurement
instruments should be evaluated to refine the selected set of
outcomes and measures. Ideally, pragmatic trials directly pro-
vide a valid and sufficiently precise estimate of the treatment
effect to support clinical decision making [2,4,9].
The Salford Lung Study (SLS), depicted in Fig. 2 as an
example, is phase III pragmatic trial in patients with chronic
obstructive pulmonary disease (COPD) that compared usual
treatment with a novel dry-powder inhaler. Patients under-
went routine clinical care with minimal study visits to assess
the annual rate of moderate/severe COPD exacerbations as
the primary outcome. Primary endpoints were obtained
directly through the electronic medical record, whereas sec-
ondary endpoints such as quality of life and number of self-
reported instances of exacerbations were recorded at the final
12-month follow-up study visit (as to not interfere with clin-
ical practice during the study). The study and outcome mea-
surement were discussed with regulators and a health
technology assessment (HTA) agency as the main stake-
holders for this prelaunch pragmatic trial [10].
2.1. Surrogate outcomes
A surrogate outcome is a substitute for a direct
measurement of a clinical endpoint. It can be a laboratory
measurement, imaging measurement, or a physical sign
as a substitute for an endpoint that relates to how a patient
feels, functions, or survives [11]. Bone density, for instance,
can be measured as a surrogate for osteoporotic fractures.
Fig. 1. Choosing what outcomes to measure and how to measure them.
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assumed to reflect changes in the clinical endpoint of
primary interest. However, the relation between the surro-
gate endpoint and the clinical endpoint is usually uncertain,
and obtaining a precise estimate of the treatment effect
relevant for clinical decision making is generally not
possible using surrogate endpoints [1,4,12,13]. Surrogate
outcomes in a pragmatic trial, therefore, may only be
acceptable as primary endpoint when measuring a clinical
endpoint is not possible and high-quality evidence exists
on their relation with endpoints directly relevant for
decision making [8,12]. An example of acceptable
surrogate endpoint is the viral load for trials evaluating
human immunodeficiency virus treatment [14,15].
2.2. Patient-reported outcomes
Patient-reported outcomes (PROs) are outcomes provided
directly by the patient without any interpretation by others.
These outcomes often assess symptoms, such as pain or
fatigue, and their impact, interference with activities in a
patients’ daily lives, or treatment satisfaction [16,17].
Health-related quality of life (HRQoL) is a specific type of
PRO that measures the degree to which the medicalcondition or its treatment impacts an individual’s well-
being, including physical and mental domains, and can be re-
garded the ultimate effect of health care [18]. Measures may
provide preference values, expressed in utility scores, which
allow the calculation of quality-adjusted life years that are
often used in economic evaluations of a treatment. In SLS,
a COPD Assessment Test and a utility HRQoL instrument,
the EuroQol-5 dimension, were used as outcomes (Fig. 2).
PROs often are not routinely assessed in clinical prac-
tice, but rather as part of the informal assessment of the
patient’s well-being. If they can be assessed without major
interference of routine care, PROs may be optimally used
as outcomes in a pragmatic trial [16,17,19,20]. For
example, assessing PROs that are relevant for disease
management might be beneficial for the quality of health
care and simultaneously offer the opportunity to use these
data for outcome assessment in clinical trials. In this
regard, the core PROs of the National Institutes of Health
Collaboratory is a worthy initiative (Table 1) [25].
2.3. Primary and secondary outcomes
Clinical trials generally assess multiple outcomes or
endpoints to evaluate differences between treatments.
How to measure?
- EMR allows real-Ɵme collecƟon 
and monitoring of endpoint and 
safety data.
- If no GP contact in 3 months, 
paƟent is contacted by phone to 
assess (S)AEs or ADRs.
- At 12 months (end of the 
study), the final assessment of 
outcomes is conducted face-to-
face with paƟent.
- EMR data for eﬀecƟveness 
endpoints are independently 
verified by the research team.
- InvesƟgators and site staﬀ are 
responsible for detecƟng, 
documenƟng and reporƟng 
SAEs and ADRs on electronic 
case report forms (eCRFs), 
which are monitored by a 
dedicated clinical safety team.
Primary outcome definiƟon:
Moderate exacerbaƟon: paƟent
receiving an exacerbaƟon-related
prescripƟon of oral corƟcosteroids
and/or anƟbioƟc (with or without
NHS contact) not requiring
hospitalisaƟon
Severe exacerbaƟon: an exacer-
baƟon-related hospitalisaƟon
Stakeholders
- Regulators (MHRA/EMA)
- HTA agencies (NICE)
Adverse events
Clinical pracƟce
Treatment and healthcare contacts are 
registered in electronic records
Mortality Life Impact Resource use and costs
Pathophysiological 
ManifestaƟons
Eﬀect modificaƟon
disease duraƟon, COPD maintenance
therapy, smoking status, lung funcƟon, 
medical history
- Secondary endpoints include Ɵme to 
first exacerbaƟon and health care 
uƟlizaƟon.
- Other endpoints include 
hospitalizaƟons, use of rescue 
medicaƟon, the COPD Assessment Test 
(CAT) and EuroQoL-5 dimensions (EQ-
5D) quesƟonnaire
- Safety endpoints include death, 
pneumonia, frequency and type of SAEs, 
and ADRs. 
Previous studies/Literature
ExacerbaƟon typically used as primary 
outcome in COPD trials 
What to measure?
Life impact, resource use and 
adverse events most relevant 
primary endpoint : mean annual rate of moderate/severe exacerbaƟons
- PaƟents randomized to their usual 
maintenance therapy are retrained in 
the correct techniques and dosing and 
paƟents randomized to the novel dry-
powder inhaler were instructed on the 
correct use of the inhaler
- RandomisaƟon is straƟfied by baseline 
maintenance therapy and history of 
COPD exacerbaƟon in the previous 12 
months (yes/no)
- Subgroup analyses will be defined based 
on e.g. baseline medicaƟon, lung 
funcƟon and comorbidiƟes.
Fig. 2. Outcomes in the Salford Lung Study. MHRA, Medicines and Healthcare products Regulatory Agency; EMA, European Medicines Agency;
HTA, health technology assessment; NICE, National Institute for Health and Clinical Excellence; COPD, chronic obstructive pulmonary disease;
SAEs, serious adverse events; ADRs, adverse drug reactions; EMR, electronic medical record; GP, general practitioner; NHS, National Health
Service.
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sufficient statistical power to detect or refute a relevant
difference between treatments on the primary outcome.
Secondary outcome measures are evaluated more explor-
atively, and a larger sample size may be needed to provide
sufficient statistical power. Therefore, using outcomes of
interest as secondary outcomes only may result in impre-
cise effect estimates complicating decision making. The
primary outcome in a pragmatic trial should therefore be
the outcome most influential for the clinical decision, the
total set of outcomes measured in a trial should reflect
all important effects of the intervention, and ensuring
sufficient power for important secondary outcomes may
be needed.
Schwartz and Lellouch [1] suggested that the outcome
of a pragmatic trial should be a single criterion, or a
combination of multiple weighed criteria, relevant for
making a treatment decision in routine clinical practice.
Different outcomes can be relevant for decision making,
including outcomes such as adverse events, treatment
adherence, and comedication. Assigning weights to theirindividual importance may be difficult however; and a
different mix of outcomes can lead to the same result on
such composite outcome, which might complicate the
interpretation [8]. An advantage of a composite endpoint
is that it may yield higher power and feasibility of
executing the trial compared with separate outcomes with
a low incidence. Although different outcomes with
congruent results will strengthen the conclusions of the
study, contradicting results can complicate it. For
example, in a study, it may be found that a new antiallergy
treatment decreases the symptom score but simultaneously
increases the use of concomitant immunotherapy [30]. In
addition, the evaluation of multiple outcomes will increase
the overall chance of type I errors. To control this type
1 error, several options are available, but they may
decrease precision of the results or necessitate a larger
sample size to have sufficient power to detect a
difference on all outcomes [31,32]. More conservative
P-values, decision rules specified a priori, or gatekeeping
procedures can be used. An example of a decision rule
can be that success may only be claimed if there is a
Table 1. International initiatives for harmonization of outcome measurements
The Core Outcome Measures in Effectiveness Trials
www.comet-initiative.org
Brings together standardized sets of outcomes in a database that can be
searched on disease, type of intervention, and stakeholders involved.
These sets represent the minimum that should be reported in all clinical
trials of a specific condition, making it easier for the results of trials to be
compared, contrasted, and/or combined. This can be a useful resource for
selecting outcomes, and the website contains
useful references for core outcome set developers
as well [21].
Outcome Measures in Rheumatology (OMERACT)
http://www.omeract.org/omeract_publications.php
Is one of the oldest initiatives standardizing outcome measures in clinical
trials that is still active. Although this initiative focuses on rheumatology,
several resources relevant for a broader disease range are available on their
website like the OMERACT Handbook on developing core outcome
measurement sets [7].
International Consortium for Health Outcomes
Measurement (ICHOM)
https://www.linkedin.com/company-beta/2760048/
Aims to transform health care systems worldwide by measuring and reporting
patient outcomes in a standardized way in daily practice. Focus is on
outcomes related to questions patients have regarding the impact of
treatment on their life. ICHOM advocates to define standard sets of
outcomes per medical condition and then drives adoption to enable health
care providers globally to compare, learn, and improve [22,23].
Healthmeasures.net
http://www.healthmeasures.net/
A useful resource bringing together four flexible and comprehensive
measurement systems. These assess physical, mental, and social health,
symptoms, well-being, and life satisfaction; along with sensory, motor, and
cognitive functions. It also provides guidance for their use [24].
Core Patient Reported Outcomes of the NIH Collaboratory
https://www.nihcollaboratory.org/cores/Pages/default.aspx
Aims to create guidelines and define best practices with respect to selecting
the most appropriate PRO measures and stimulates the development of
new instruments when needed, creating efficient, high-quality PRO data
collection systems
compatible with electronic health records and registries and conducting
statistical analyses of
PRO endpoints [25].
The COnsensus-based Standards for the selection of health
Measurement Instruments
http://www.cosmin.nl
Aims to improve the selection of health measurement instruments among
others by providing a tool on standards for evaluating the quality of studies
on measurement properties of measurement
instruments [26].
Global HealthCare system roadmaps and
PharmacoEconomic guidelines around the world
Eldessouki R, Smith MD. Health care system information
sharing: a step toward better health globally. Value Health
Reg Issues 2012;1:118e129.
http://www.ispor.org/HTARoadmaps/Default.asp
http://www.ispor.org/peguidelines/index.asp
These tools from the International Society of Pharmacoeconomics and
Outcomes Research may be a useful resource for evaluating and
comparing country- and agency-specific outcome preferences. On these
website, HTA requirements and decision processes with country-/region-
specific information on preferred outcomes and preference for efficacy or
effectiveness and generalizability of results among many more
characteristics of the evidence requirements can be searched and
compared in tables [27e29].
Abbreviations: NIH, National Institutes of Health; PRO, patient-reported outcome; HTA, health technology assessment.
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keeping procedures entail organizing primary and second-
ary hypotheses of interest a priori, and only proceed with
testing when the significance criteria for the previous
hypothesis are satisfied. The final selection of outcomes
in pragmatic trials should be relevant for decision making
and feasible in terms of trial conduct.
2.4. Satisfying all stakeholders
Stakeholders in the prelaunch and postlaunch phases
may have different priorities or requirements for study out-
comes. The pharmaceutical industry and regulatory
agencies are the most important stakeholders for prelaunch
drug trials, whereas after market release, these are mainly
HTA agencies, payers, health care providers, and patients.
Study outcomes for a pragmatic trial performed in the pre-
launch phase should probably aim to satisfy outcomerequirements for prelaunch and postlaunch stakeholders
requiring careful discussions with these stakeholders as
done in the SLS (Fig. 2). Regulatory agencies typically
assess efficacy and safety using (prelaunch) explanatory
randomized controlled trials, whereas HTA agencies also
evaluate more pragmatic or observational studies and may
use meta-analytic approaches. The European Medicine
Agency states that HRQoL measures are generally not
acceptable as a primary outcome, and they also state that
surrogate endpoints may be used as primary endpoints
[33,34]. The EUnetHTA guidelines recommend to include
a disease- or population-specific and a generic HRQoL
measure that adequately captures the impact of a disease
on daily life. The relative effectiveness assessment of
pharmaceuticals should be based where possible on
patient-relevant clinical endpoints such as morbidity and
overall mortality [8]. Furthermore, outcomes that are
considered important by research physicians are not
104 P.M. Welsing et al. / Journal of Clinical Epidemiology 90 (2017) 99e107necessarily important for patients [35e38]. For example, it
was found that heart failure patients deem the absence of
dyspnea important, although this was generally not an
endpoint in hearth failure trials [39]. Patients with diabetes
find mortality, the development of kidney failure, and
dialysis dependence more important than HbA1c levels, a
surrogate outcome typically used as a primary outcome,
although these preferred outcomes may influence the feasi-
bility of conducting the trial [13]. Collaboration between
patients with rheumatoid arthritis and the rheumatology
research community has identified that fatigue is often an
outcome of top priority, often ranking as high or higher
than pain as outcome. These findings have led to interna-
tional consensus that fatigue should be measured in all
clinical trials in addition to the existing core set of outcome
measures for clinical trials [40].
The different opinions and requirements related to out-
comes should be discussed with all stakeholders (Fig. 1).
Several international initiatives and resources exist bringing
together the so-called core outcome sets, stimulating the
consistent measurement of relevant outcomes in clinical
practice and trials. These core outcome sets also enable
easier comparison of study results and are generally devel-
oped with involvement of different stakeholders. They are
directly relevant for pragmatic trials when all relevant stake-
holder views are taken into account, and measurements do
not interfere with usual practice to an extent that results
are no longer generalizable. Otherwise existing sets and re-
sources can be helpful in selecting and agreeing on a set of
outcomes and how to measure them for a specific study and
indication, group of stakeholders, and/or region (Table 1).3. Measuring outcomes
Instruments to assess the outcome should be sufficiently
accurate (ie, valid, reliable, and responsive) and feasible in
terms of costs and complexity [41e43]. Deviations from
routine clinical practice should be minimized, also to pro-
mote the acceptability of measurements to patients and care
providers who participate in a study [7,44-46]. It may be
beneficial for decision making to apply a predefined cutoff
value for continuous outcome measures in a pragmatic trial
when resulting categorical outcomes have a clearer mean-
ing for interpretation of trial results at patient level (ie,
the probability of recovery). For example, in an explanatory
trial studying the biologic effect of treatment for high blood
pressure, the decrease in millimeters of mercury in systolic
blood pressure could be the main outcome, whereas in a
pragmatic trial, a drop in systolic blood pressure below
130 mm Hg may be more appropriate as primary outcome.
For some outcomes, the concept of minimally clinically
important difference may be useful to define such cutoff
[47,48]. Using a predefined cutoff also poses disadvantages
such as loss of precision [49].3.1. Routinely collected data to define outcomes
Data that are recorded in (electronic) medical files during
routine clinical practice should be preferred as outcomes in
pragmatic trials. Many algorithms have been created to
define outcomes based on data that have been routinely
recorded in electronic health files [50e53]. Ricketts et al.
[50] developed an algorithm to define progression-free
survival in patients with head and neck cancer, using data
on patient admission, chemotherapy, and radiotherapy. This
automated technique resulted in progression-free survival
estimates in line with what was found by manual chart
review in 82% of the patients [50]. Based on the instances
of diarrhea and fatigue recorded in the electronic health
record, nonresponse, partial, or complete response have been
calculated after 1 year of treating patients with Crohn disease
or ulcerative colitis with antibodies to tumor necrosis factor
alpha, which correlated well with the need for surgery and
hospitalization [51]. Rubbo et al. [52] reviewed 31 studies
on the validity of an automated diagnosis of acute myocar-
dial infarction and found positive predictive values of more
than 70%. Although these outcome definitions can be
useful in pragmatic trials, such algorithms are generally only
validated for the specific data set and may need to be
validated or newly developed and validated for a specific trial
[53], which can increase complexity and may delay the trial.3.2. Accurate and complete outcome assessment
Accurate and complete measurement of relevant out-
comes is key for the validity and precision of trial results
and applicability of the results in clinical practice. In
contrast to explanatory trials, outcomes in a pragmatic trial
should be measured with the inclusion of extraneous effects
of comedication, nonadherence, and placebo effects. In
pragmatic trials, therefore, patients and physician are often
aware of the treatment group (ie, not blinded) as knowledge
of the treatment (including related placebo effects and
effects on care) is part of real-world practice. Patients
who are not treated according to the protocol should also
remain followed for the collection of outcome data if
possible to enable a true intention-to-treat analysis [3,54].
Self-reported and subjective outcomes can be valuable
indicators of disease impact; however, they may be sensi-
tive to observer bias. For example, when opinions about
the merits and disadvantages differ between treatments
compared, physicians and patients may (unintentionally)
report the severity of the disease differently or tend to
report safety concerns quicker on new treatment [55,56].
Although patients and physicians should not be blinded,
blinded outcome assessment, if possible, is recommended
to minimize observer bias in pragmatic trials [57].
Measurements in practice may also be performed in a less
uniform way, leading to higher variability in outcomes
necessitating a higher sample size for the study or even
resulting in biased estimates of effectiveness [58,59]. When
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overestimating the actual outcome, this results in biased
estimates of comparative treatment effect. Standardization
of measurement and/or training of assessors may increase
the precision of measurements and a measurements’ valid-
ity and may make it less subjective. Standardization and
training also increase complexity and may compromise
generalizability but should be considered when not doing
so would compromise the precision and/or validity of
results. An external adjudication committee can be installed
for a blinded and uniform assessment of the outcome,
which may take away the need to train physicians on
standardized outcome assessment. However, adjudicating
intermediate outcomes (eg, osteoporosis) does not reflect
clinical practice, and the adjudicated outcome does not
represent future actions based on the presence of osteopo-
rosis and the development of final outcomes (eg, fractures).
The value of adjudication for validity and precision of trial
results is not certain, and it also increases the complexity
and decreases the feasibility of the trial, and therefore, its
use should be determined on a per-trial basis [60].
When clinical examinations are only prompted by
physical complaints, this may lead to missing outcome
data that can jeopardize the validity, generalizability,
and/or precision of the study results. The impact of
missing data on the results of the study depends on the
reason why data are missing and can be addressed by
several approaches as described elsewhere [61]. Data that
are missing completely at random will not systematically
affect or bias the outcome measurement (but do decrease
precision). When data are missing at random, biases can
be overcome using methods such as multiple imputation,
where missing values are replaced by appropriate estima-
tions based on nonmissing data, that allow individuals
with incomplete data to be included in analyses. Biases
caused by data that are missing not at random can only
be addressed by sensitivity analyses that examine the
effects of different missing data assumptions. As
pragmatic trials follow routine practice as closely as
possible, measurements may be more variable, and
missing values may be more pertinent than in explanatory
trials when not routinely performed. A feasibility study
may identify the key challenges and can be helpful to
adapt the design where needed to obtain valid and precise
outcome measurements (Fig. 1).4. Additional measurements
Characteristics of the patient, disease, and setting of the
trial can modify the treatment effect. Measuring potential
effect modifiers, such as age, socioeconomic status, ethnicity,
type of medical practice, comorbidity, concomitant medica-
tion, and treatment adherence, can help to clarify whether
the study population in the pragmatic trial is comparable to
the patients who are encountered in clinical practice
(Fig. 1). Furthermore, exploring the relation betweentreatment effect and effect modifiers could improve the un-
derstanding of the treatment effect in subgroups and may
help to explain differences between pragmatic and explana-
tory clinical trials investigating the same intervention [62].
Formally studying effect modification in the study will affect
sample size or require oversampling of subgroups [62].5. Conclusion
Estimates of treatment effect in pragmatic trials should
be directly generalizable to clinical practice and relevant
to patients and decision making in real-world clinical
practice. The primary outcome should typically be the
outcome most relevant for the research question and deci-
sion problem at hand and analysis based on the true
intention-to-treat population. Outcome measurement
should not interfere with usual practice, and routinely
collected outcome measures should therefore be preferred.
Relevance, feasibility, interference with practice, validity,
and precision of outcome measurement should be evaluated
with all stakeholders, and the final set of outcomes and
measures may be more tailor-made, and choices should
therefore be reported clearly.Acknowledgments
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